The results from a prospective clinical study on CercaTest RED™ was presented in the Asia Pacific Congress in Maternal Fetal Medicine 2025 (APCMFM) held from November 1 to 3 in Osaka, Japan.

The Asia-Pacific Congress of Maternal-Fetal Medicine (APCMFM) is one of the most influential academic conferences in the field of maternal fetal medicine in the Asia-Pacific region.

CercaTest RED™ is a patent-protected point-of-care test for detection of misfolded proteins in urine samples to aid in the diagnosis and screening of preeclampsia after the 20th week of pregnancy. Preeclampsia is a hypertensive syndrome that complicates 2 to 8% of all pregnancies and accounts for about 70,000 maternal deaths and 500,000 fetal or newborn deaths each year worldwide. CercaTest RED™ is non-invasive and easy to use, providing results within 10 minutes. It is a CE marked product, and has been approved in China for both professional and home testing.

During the first day of the Conference, Dr. Xiaoxia Bai from Women’s Hospital of Zhejiang University School of Medicine presented a multicenter prospective longitudinal study using CercaTest RED™ involving 365 women suspected of having preeclampsia. When the CercaTest RED™ test results were combined with clinical parameters into a prediction model, a high accuracy was demonstrated in predicting preeclampsia within one week of clinical diagnosis, with an AUC 0.937 (95 % CI 0.911–0.964), PPV 54.4 % (95 % CI 44.3–63.7 %) and NPV 97.7 % (95 % CI 95.3–99.1 %). For severe preeclampsia the AUC rose to 0.955.

“CercaTest RED™ is a urine-based one-step test that can be performed by pregnant women or professionals with almost instant result,” said Dr. Xiaoxia Bai, “Our study suggests that it could offer significant value in early detection in clinical settings and at home for early intervention, thereby improving maternal and fetal outcomes.”